Related Experiment Videos
Hypervariable region diversity of hepatitis C virus and humoral response: comparison between patients with or without
1Department of Haematology, University of Cambridge, United Kingdom. jpa1000@cam.ac.uk
Insights
Antibody responses to Hepatitis C Virus (HCV) HVR1 peptides show distinct patterns in chronic carriers. Non-cirrhotic patients exhibit higher antibody cross-reactivity to C-terminal HVR1, suggesting potential clinical utility in assessing liver disease progression.
Area of Science:
- Immunology
- Virology
- Hepatology
Background:
- Antibody responses to the Hepatitis C Virus (HCV) hypervariable region 1 (HVR1) are crucial for viral control.
- Understanding HVR1 diversity and antibody reactivity is key to developing effective HCV therapies and diagnostics.
Purpose of the Study:
- To investigate the clinical utility of antibody responses to HCV HVR1.
- To compare genomic and amino acid diversity of HVR1 in chronic HCV carriers with and without liver cirrhosis.
- To assess the reactivity of patient sera to autologous and homologous HVR1 epitopes.
Main Methods:
- Comparative analysis of HVR1 genomic and amino acid diversity in two groups of chronic HCV carriers.
- Synthesis of peptides corresponding to COOH- and NH2-terminal HVR1 sequences.
- Enzyme-linked immunosorbent assay (ELISA) to assess patient serum reactivity to HVR1 peptides.
Main Results:
- Chronic HCV carriers showed significantly more frequent cross-reactivity with homologous C-terminal HVR1 peptides compared to N-terminal.
- Frequency of cross-reactivity with C- or N-terminal HVR1 peptides was similar between cirrhotic and noncirrhotic patients.
- Non-cirrhotic patients displayed a significantly higher level of C-terminal HVR1 antibody cross-reactivity than cirrhotic patients.
Conclusions:
- The magnitude of the immune response to C-terminus HVR1 peptides, but not the frequency of cross-reactivity, differs between HCV chronic carriers with and without liver cirrhosis.
- Antibody response to HVR1 may serve as a potential biomarker for liver disease progression in HCV infection.
Abstract:
To investigate the potential clinical utility of antibody response to HVR1 of HCV, the genomic and amino acid diversity of HVR1 was compared between two groups of four chronic HCV carriers with or without liver cirrhosis. Peptides corresponding to the deduced COOH- and NH2-terminal amino acid sequences of HVR1 were synthesised to assess the reactivity of patient sera to autologous and homologous HVR1 epitopes by enzyme-linked immunosorbent assay. HCV chronic carriers had significantly more frequent cross-reactivity with homologous C- than N-terminal HVR1 peptides. Twelve cirrhotic and eleven noncirrhotic patients had a similar frequency of cross-reactivity with either C- or N-terminal HVR1 peptides. However, noncirrhotic patients had a significantly higher level of C-terminal HVR1 antibody cross-reactivity than cirrhotic patients. In HCV chronic carriers, the magnitude of the immune response to but not the frequency of cross-reactivity with C-terminus HVR1 peptides differ between patients with and without liver cirrhosis.